Abstract
Objective
To investigate the effect of infliximab treatment on antinuclear antibodies (ANAs), anti–double‐stranded DNA (anti‐dsDNA), antinucleosome, antihistone, and anti–extractable nuclear antigen (anti‐ENA) antibodies in rheumatoid arthritis (RA) and spondylarthropathy (SpA) patients.
Methods
Sera from 62 RA and 35 SpA patients treated with infliximab were tested at baseline and week 30 (RA group) or week 34 (SpA group). ANAs were tested by indirect immunofluorescence (IIF) on HEp‐2 cells. Anti‐dsDNA antibodies were detected by IIF on Crithidia luciliae and by enzyme‐linked immunosorbent assay (ELISA) and were further isotyped with γ, μ, and α chain–specific conjugates at various time points. Antinucleosome antibodies were tested by ELISA. Antihistone and anti‐ENA antibodies were detected by line immunoassay.
Results
Initially, 32 of 62 RA patients and 6 of 35 SpA patients tested positive for ANAs. After infliximab treatment, these numbers shifted to 51 of 62 (P < 0.001) and 31 of 35 (P < 0.001), respectively. At baseline, none of the RA or SpA patients had anti‐dsDNA antibodies. After infliximab treatment, 7 RA patients (P = 0.016) and 6 SpA patients (P = 0.031) became positive for anti‐dsDNA antibodies. All 7 anti‐dsDNA–positive RA patients had IgM and IgA anti‐dsDNA antibodies. Three of the 6 anti‐dsDNA–positive SpA patients had IgM and IgA anti‐dsDNA antibodies, and 2 had IgM anti‐dsDNA antibodies alone. In both diseases, the IgM anti‐dsDNA antibodies appeared before the IgA anti‐dsDNA antibodies. During the observation period, no IgG anti‐dsDNA antibodies or lupus symptoms were observed. The development of antinucleosome, antihistone, or anti‐ENA antibodies following infliximab treatment was observed in some patients, but the numbers were not statistically significant.
Conclusion
Infliximab treatment may induce ANAs, and especially IgM and IgA anti‐dsDNA antibodies, in RA and SpA patients. However, no anti‐dsDNA IgG antibodies or lupus symptoms were observed during the period of observation in this study, and the development of antinucleosome, antihistone, or anti‐ENA antibodies was not statistically significant. These observations do not exclude potential induction of clinically significant lupus in the long term, and further followup is therefore mandatory.